These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3882141)

  • 61. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings.
    Ringdén O; Klaesson S; Sundberg B; Ljungman P; Lönnqvist B; Persson U
    Bone Marrow Transplant; 1992 Jan; 9(1):19-25. PubMed ID: 1543946
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate.
    Kanda Y; Izutsu K; Hirai H; Sakamaki H; Iseki T; Kodera Y; Okamoto S; Mitsui H; Iwato K; Hirabayashi N; Furukawa T; Maruta A; Kasai M; Atsuta Y; Hamajima N; Hiraoka A; Kawa K
    Leukemia; 2004 May; 18(5):1013-9. PubMed ID: 15029208
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cyclosporine in human bone marrow transplantation. Serum concentration, graft-versus-host disease, and nephrotoxicity.
    Gratwohl A; Speck B; Wenk M; Forster I; Müller M; Osterwalder B; Nissen C; Follath F
    Transplantation; 1983 Jul; 36(1):40-4. PubMed ID: 6346614
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation.
    Holler E; Kolb HJ; Hiller E; Mraz W; Lehmacher W; Gleixner B; Seeber C; Jehn U; Gerhartz HH; Brehm G
    Blood; 1989 May; 73(7):2018-24. PubMed ID: 2496776
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Profound hypomagnesemia and renal magnesium wasting associated with the use of cyclosporine for marrow transplantation.
    June CH; Thompson CB; Kennedy MS; Nims J; Thomas ED
    Transplantation; 1985 Jun; 39(6):620-4. PubMed ID: 3890292
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia.
    Storb R; Martin P; Deeg HJ; Sanders JE; Pepe M; Singer J; Anasetti C; Stewart P; Appelbaum FR; Sullivan KM
    Blood; 1992 Jun; 79(11):3091-2. PubMed ID: 1586751
    [No Abstract]   [Full Text] [Related]  

  • 68. Dermatological aspects of the use of Cyclosporin A for prophylaxis of graft-versus-host disease.
    Harper JI; Kendra JR; Desai S; Staughton RC; Barrett AJ; Hobbs JR
    Br J Dermatol; 1984 Apr; 110(4):469-74. PubMed ID: 6370294
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients.
    June CH; Thompson CB; Kennedy MS; Loughran TP; Deeg HJ
    Transplantation; 1986 Jan; 41(1):47-51. PubMed ID: 3510494
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation.
    Kennedy MS; Deeg HJ; Siegel M; Crowley JJ; Storb R; Thomas ED
    Transplantation; 1983 Mar; 35(3):211-5. PubMed ID: 6340275
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation.
    Heimdahl A; Mattsson T; Dahllöf G; Lönnquist B; Ringdén O
    Oral Surg Oral Med Oral Pathol; 1989 Dec; 68(6):711-6. PubMed ID: 2594318
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cyclosporine.
    Ptachcinski RJ; Burckart GJ; Venkataramanan R
    Drug Intell Clin Pharm; 1985 Feb; 19(2):90-100. PubMed ID: 3882378
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hypertension in bone marrow transplanted patients.
    De Plaen JF; Ferrant A; Michaux JL; van Ypersele de Strihou C
    Acta Clin Belg; 1989; 44(5):295-302. PubMed ID: 2692366
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Renal cyclosporine clearance in marrow transplant recipients: age-related variation.
    Yee GC; Mills G; Schaffer R; Lennon TP; Kennedy MS; Deeg HJ
    J Clin Pharmacol; 1986; 26(8):658-61. PubMed ID: 3540031
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk factors for acute graft-versus-host disease associated with cyclosporine and methotrexate prophylaxis.
    Russell N; Rogers S; Hunter A
    Blood; 1993 Apr; 81(7):1972-4. PubMed ID: 8507260
    [No Abstract]   [Full Text] [Related]  

  • 76. Cyclosporine--a model for the testing of bio-immunological reaction modifiers in man.
    Powles RL; Evans B; Pedrazzini A; Crofts M; Hill P; Westensee W
    Med Oncol Tumor Pharmacother; 1984; 1(2):137-9. PubMed ID: 6400032
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cyclosporine in allogeneic bone marrow transplantation.
    Ringdén O
    Transplantation; 1986 Nov; 42(5):445-52. PubMed ID: 3538528
    [No Abstract]   [Full Text] [Related]  

  • 78. [Peripheral neuropathy investigation in the early stage of bone marrow transplantation].
    Zétola VH; Scola RH; Pasquini R; Werneck LC
    Arq Neuropsiquiatr; 1998 Jun; 56(2):267-73. PubMed ID: 9698739
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease.
    Hess AD; Fischer AC
    Transplantation; 1989 Dec; 48(6):895-900. PubMed ID: 2688206
    [No Abstract]   [Full Text] [Related]  

  • 80. Systemic hypertension associated with cyclosporine: a review.
    Weidle PJ; Vlasses PH
    Drug Intell Clin Pharm; 1988 Jun; 22(6):443-51. PubMed ID: 3293956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.